Palliative therapy of bone metastases by Radiopharmaceuticals
- Conditions
- Condition 1: Bone metastasis. Condition 2: Malignant neoplasms.Malignant neoplasm of bone and articular cartilage of limbsMalignant neoplasm of bone and articular cartilage of other and unspecified sites
- Registration Number
- IRCT201109181100N3
- Lead Sponsor
- Vice chancellor for research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria: Patients (>20 yr) with multiple skeletal metastasis of a known cancer who have intractable bone pain; Multiple painful bone metastases; Positive bone scan (within 6 wk); abnormal uptake (>1 site) corresponding to pain sites; Estimated life expectancy 2 months especially for agents with longer half-life; No chemotherapy or external beam radiation during 4-6 weeks before therapy with agent (This is particularly important when long-acting agents such as nitrosoureas have been given); WBC>2500 (some reports 3500); Platelet>60,000.
Acute or chronic renal failure; Acute spinal cord suppression; who need to external radiation therapy; A solitary metastatic site; Extensive soft tissue metastases; Evidence of disseminated intravascular coagulopathy; Prior to myelosuppressive chemotherapy; Impending pathologic fracture; Hemoglobin < 90 g.L-1; Total white cell count < 2500 (some reports 3500); Absolute neutrophil count < 1500; Platelets < 60,000; Glomerular filtration rate < 30 mL/min; Pregnancy; breastfeeding; women of child-bearing age.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone pain. Timepoint: 2, 4 and 8 weeks elapsed from intervention. Method of measurement: Standardized questionaire.
- Secondary Outcome Measures
Name Time Method Bone marrow suppression. Timepoint: 2, 4 and 8 weeks elapsed from intervension. Method of measurement: Peripheral cell blood count.